scispace - formally typeset
J

Joseph L. Izzo

Researcher at University at Buffalo

Publications -  232
Citations -  53804

Joseph L. Izzo is an academic researcher from University at Buffalo. The author has contributed to research in topics: Blood pressure & Systolic hypertension. The author has an hindex of 46, co-authored 229 publications receiving 51755 citations. Previous affiliations of Joseph L. Izzo include Erie County Medical Center & LSU Health Sciences Center New Orleans.

Papers
More filters
Journal ArticleDOI

Insulin Attenuates Norepinephrine- Induced Venoconstriction: An Ultrasonographic Study

Anil Grover, +5 more
- 01 Apr 1995 - 
TL;DR: Methylene blue, an inhibitor of guanylate cyclase, was infused simultaneously with 32 microU/min insulin and 100 ng/min norepinephrine, which inhibited the venodilator effect of insulin and caused highly reproducible dose-dependent increases in mean venous diameter.
Journal ArticleDOI

Hemodynamics of Seasonal Adaptation

Joseph L. Izzo, +3 more
- 01 May 1990 - 
TL;DR: In the northern US, wintertime vasoconstriction is related to increased sympathetic nervous activity and decreased cardiac output, and when these reciprocal changes are proportional, blood pressure remains constant.
Journal ArticleDOI

Augmentation index and central aortic stiffness in middle-aged to elderly individuals

Mitul Vyas, +7 more
- 01 Jun 2007 - 
TL;DR: Increased AI is not a reliable surrogate for increased aortic stiffness and may be attributable to impedance matching and reduced wave reflection at the interface between the aorta and the muscular arteries.
Journal ArticleDOI

Captopril Reduces Urinary Cystine Excretion in Cystinuria

James A. Sloand, +1 more
- 01 Aug 1987 - 
TL;DR: The first clinical use of captopril in the treatment of homozygous cystinuria in two siblings is reported, with a 70% reduction in cystine excretion after 26 weeks of therapy with 150 mg/d ofcaptopril.
Journal ArticleDOI

Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure

Aileen B. Luzier, +6 more
- 15 Aug 1998 - 
TL;DR: Clinical usage of digoxin, diuretic, and angiotensin-converting enzyme (ACE) inhibitor was assessed in patients readmitted over a 36-month period for congestive heart failure, and readmission rates are lower when daily ACE inhibitor doses exceed 5 mg enalapril or the equivalent daily, but are unaffected by digoxin or diUREtic.